Heart safety check for new Weight-Loss drug candidate
Knowledge-focused
Not yet recruiting
This phase 1 study investigates whether ZT002 (zovaglutide), an experimental injectable drug given every two weeks, affects the heart's electrical activity in overweight or obese adults. Researchers compare changes in the QT interval—a measure of heart rhythm—between those receiv…
Phase: PHASE1 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC